<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>M Napier | Tristan Snowsill</title>
    <link>/author/m-napier/</link>
      <atom:link href="/author/m-napier/index.xml" rel="self" type="application/rss+xml" />
    <description>M Napier</description>
    <generator>Source Themes Academic (https://sourcethemes.com/academic/)</generator><language>en-us</language><copyright>Â© 2020 Tristan Snowsill</copyright><lastBuildDate>Sun, 01 Jul 2018 00:00:00 +0000</lastBuildDate>
    <image>
      <url>/images/icon_hu050d7ab96a8b87ebb29a3f4b58eca100_52805_512x512_fill_lanczos_center_2.png</url>
      <title>M Napier</title>
      <link>/author/m-napier/</link>
    </image>
    
    <item>
      <title>Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England</title>
      <link>/publication/tikhonova-2018-economic-analysis-of-first-line-treatment-with-cetuximab/</link>
      <pubDate>Sun, 01 Jul 2018 00:00:00 +0000</pubDate>
      <guid>/publication/tikhonova-2018-economic-analysis-of-first-line-treatment-with-cetuximab/</guid>
      <description></description>
    </item>
    
    <item>
      <title>The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: A systematic review and economic evaluation</title>
      <link>/publication/huxley-2017-the-clinical-effectiveness-and-cost-effectiveness-of-cetuximab/</link>
      <pubDate>Sun, 01 Jan 2017 00:00:00 +0000</pubDate>
      <guid>/publication/huxley-2017-the-clinical-effectiveness-and-cost-effectiveness-of-cetuximab/</guid>
      <description></description>
    </item>
    
    <item>
      <title>The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): A systematic review and economic model</title>
      <link>/publication/crathorne-2016-the-effectiveness-and-cost-effectiveness-of-erythropoiesis/</link>
      <pubDate>Mon, 01 Feb 2016 00:00:00 +0000</pubDate>
      <guid>/publication/crathorne-2016-the-effectiveness-and-cost-effectiveness-of-erythropoiesis/</guid>
      <description></description>
    </item>
    
    <item>
      <title>MODEL-BASED COST-UTILITY ANALYSIS OF ERYTHROPOIESIS-STIMULATING AGENTS FOR THE TREATMENT OF CANCER-TREATMENT INDUCED ANAEMIA IN THE UK NHS</title>
      <link>/publication/snowsill-2014-model-based-cost-utility-analysis-of-erythropoiesis-stimulating-agents/</link>
      <pubDate>Sat, 01 Nov 2014 00:00:00 +0000</pubDate>
      <guid>/publication/snowsill-2014-model-based-cost-utility-analysis-of-erythropoiesis-stimulating-agents/</guid>
      <description></description>
    </item>
    
    <item>
      <title>1498P WHAT IS THE CLINICAL EFFECTIVENESS OF ERYTHROPOIESIS STIMULATING AGENTS FOR THE TREATMENT OF CANCER TREATMENT-INDUCED ANAEMIA?</title>
      <link>/publication/crathorne-2014-what-is-the-clinical-effectiveness-of-erythropoiesis/</link>
      <pubDate>Mon, 01 Sep 2014 00:00:00 +0000</pubDate>
      <guid>/publication/crathorne-2014-what-is-the-clinical-effectiveness-of-erythropoiesis/</guid>
      <description></description>
    </item>
    
    <item>
      <title>A COST-EFFECTIVENESS ANALYSIS OF ERYTHROPOIESIS-STIMULATING AGENTS FOR TREATING CANCER-TREATMENT INDUCED ANAEMIA</title>
      <link>/publication/huxley-2014-a-cost-effectiveness-analysis-of-erythropoiesis-stimulating/</link>
      <pubDate>Mon, 01 Sep 2014 00:00:00 +0000</pubDate>
      <guid>/publication/huxley-2014-a-cost-effectiveness-analysis-of-erythropoiesis-stimulating/</guid>
      <description></description>
    </item>
    
  </channel>
</rss>
